Gilead Sciences posted on LinkedIn:
“Gilead News: In an open letter, Chairman and Chief Executive Officer Daniel O’Day discusses our just-approved HIV prevention medication and its role in our fight to help end the epidemic.”
More posts featuring Gilead Sciences.